Mymetics is focused on several pathways to develop prophylactic vaccines and immunotherapies with virosomes:

  • The ability to build a first line of defence against viruses entering the blood stream by focusing on the mucosal layer and generating mucosal and serum antibodies
  • Improve the working of the immune system through generation of specific CD4+ and CD8+ T cells, especially needed for oncology immunotherapies
  • The development of a thermostable and cold chain virosome vaccine formulations that can be administered through intra-nasal, sub lingual or oral routes.

Using these pathways, our pipeline comprises vaccine candidates at various stages of clinical development under our own development or in collaboration with partners.

Mymetics is focused on several pathways to develop prophylactic vaccines and immunotherapies with virosomes:


Two highly contagious viruses, with a high prevalence in developed countries, causing respiratory tract infections in patients of all ages. While seasonal Flu vaccines, efficacy can be improved and longer and broader protection is sought after. For RSV, there is currently no approved vaccine available.


With over 35 million victims, HIV/AIDS is still in the top 10 cause of mortality worldwide, and the leading cause of death in sub-Saharan Africa. In 2020, the number of people living with HIV was estimated at 37 million. That same year 1.5 million new people were infected with the virus and 690,000 deaths were caused by HIV (source: WHO, UNAIDS).


Malaria is an entirely preventable and treatable mosquito-borne illness, but still caused 435,000 deaths in 2017… we are developing a transmission blocking malaria vaccine.


New oncology immunotherapies, especially in the field of check point blockade / inhibitors, have provided significant progress in the treatment of certain cancers. Besides the proven safety and immunogenicity track record of virosome vaccines to generate antibodies, Mymetics’ virosomes are known to be able to trigger CD4+ and also CD8+ T cells through MHC-I presentation, providing an excellent platform to improve cancer immune therapies.


COVID-19 (coronavirus disease 2019) is defined as illness caused by the newly discovered coronavirus SARS-CoV-2. It was initially reported to the World Health Organization (WHO) on December 31, 2019. Coronaviruses (CoV) represent a large family of viruses which may cause illness in humans ranging from the common cold to serious illness. The most recently discovered coronavirus (SARS-CoV-2) caused the current global pandemic, which now poses major challenges to almost all countries.